{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:20:57Z","timestamp":1795062057396,"version":"4.10.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report the results of a Phase I radiation dose escalation study using an yttrium-90 (\n                    <jats:sup>90<\/jats:sup>\n                    Y) labelled anti-CD66 monoclonal antibody given with standard conditioning regimen for patients receiving haematopoietic stem cell transplants for myeloid leukaemia or myeloma. The\n                    <jats:sup>90<\/jats:sup>\n                    Y-labelled anti-CD66 was infused prior to standard conditioning. In total, 30 patients entered the trial and 29 received\n                    <jats:sup>90<\/jats:sup>\n                    Y-labelled mAb, at infused radiation activity levels of 5, 10, 25, or 37.5\u2009megaBequerel (MBq)\/kg lean body weight. A prerequisite for receiving the\n                    <jats:sup>90<\/jats:sup>\n                    Y-labelled mAb was favourable dosimetry determined by single-photon emission computerised tomography (SPECT) dosimetry following administration of indium-111 (\n                    <jats:sup>111<\/jats:sup>\n                    In) anti-CD66. Estimated absorbed radiation doses delivered to the red marrow demonstrated a linear relationship with the infused activity of\n                    <jats:sup>90<\/jats:sup>\n                    Y-labelled mAb. At the highest activity level of 37.5\u2009MBq\/kg, mean estimated radiation doses for red marrow, liver, spleen, kidneys and lungs were 24.6\u2009\u00b1\u20095.6\u2009Gy, 5.8\u2009\u00b1\u20092.7\u2009Gy, 19.1\u2009\u00b1\u20098.0\u2009Gy, 2.1\u2009\u00b1\u20091.1 and 2.2\u2009\u00b1\u20090.9, respectively. All patients engrafted, treatment-related mortality 1-year post-transplant was zero. Toxicities were no greater than those anticipated for similar conditioning regimens without targeted radiation. The ability to substantially intensify conditioning prior to haematopoietic stem cell transplantation without increasing toxicity warrants further testing to determine efficacy. clinicaltrials.gov identifier: NCT01521611.\n                  <\/jats:p>","DOI":"10.1038\/s41409-024-02317-z","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:01:32Z","timestamp":1718197292000},"page":"1247-1257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-3925","authenticated-orcid":false,"given":"Kim","family":"Orchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-2010","authenticated-orcid":false,"given":"Matthew","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Michopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Zvavamwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lewington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"2317_CR1","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","volume":"76","author":"RA Clift","year":"1990","unstructured":"Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al. Allogeneic marrow transplantatig1on in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867\u201371.","journal-title":"Blood."},{"key":"2317_CR2","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1182\/blood.V77.8.1660.1660","volume":"77","author":"RA Clift","year":"1991","unstructured":"Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77:1660\u20135.","journal-title":"Blood"},{"key":"2317_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood.V92.4.1455","volume":"92","author":"RA Clift","year":"1998","unstructured":"Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, Thomas ED. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood. 1998;92:1455\u20136.","journal-title":"Blood"},{"key":"2317_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","volume":"12","author":"EP Alyea","year":"2006","unstructured":"Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:1047\u201355.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2317_CR5","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"M Aoudjhane","year":"2005","unstructured":"Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304\u201312.","journal-title":"Leukemia"},{"key":"2317_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","volume":"104","author":"M de Lima","year":"2004","unstructured":"de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865\u201372.","journal-title":"Blood"},{"key":"2317_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","volume":"108","author":"R Martino","year":"2006","unstructured":"Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836\u201346.","journal-title":"Blood."},{"key":"2317_CR8","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1089\/scd.2014.0123","volume":"23","author":"SF Abdul Wahid","year":"2014","unstructured":"Abdul Wahid SF, Ismail NA, Mohd-Idris MR, Jamaluddin FW, Tumian N, Sze-Wei EY, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev. 2014;23:2535\u201352.","journal-title":"Stem Cells Dev"},{"key":"2317_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/bmt.2015.61","volume":"50","author":"SR Pingali","year":"2015","unstructured":"Pingali SR, Champlin RE. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2015;50:1157\u201367.","journal-title":"Bone Marrow Transplant"},{"key":"2317_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/bmt.2011.69","volume":"47","author":"SM Luger","year":"2012","unstructured":"Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47:203\u201311.","journal-title":"Bone Marrow Transplant"},{"key":"2317_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","volume":"13","author":"M Bornhauser","year":"2012","unstructured":"Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035\u201344.","journal-title":"Lancet Oncol"},{"key":"2317_CR12","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","volume":"5","author":"F Fasslrinner","year":"2018","unstructured":"Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5:e161\u20139.","journal-title":"Lancet Haematol"},{"key":"2317_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"2317_CR14","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","volume":"35","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, H\u00fcbel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35:2157\u201364.","journal-title":"J Clin Oncol"},{"key":"2317_CR15","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875\u201383.","journal-title":"N Engl J Med"},{"key":"2317_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Intergroupe Francais du Myelome et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91\u20137.","journal-title":"N Engl J Med"},{"key":"2317_CR17","first-page":"7","volume":"95","author":"S Lenhoff","year":"2000","unstructured":"Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Nordic Myeloma Study Group et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood. 2000;95:7\u201311.","journal-title":"Blood"},{"key":"2317_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","volume":"154","author":"JM Bird","year":"2011","unstructured":"Bird JM, Owen RG, D\u2019Sa S, Snowden JA, Pratt G, Ashcroft J, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154:32\u201375.","journal-title":"Br J Haematol"},{"key":"2317_CR19","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","volume":"21","author":"N Shah","year":"2015","unstructured":"Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1155\u201366.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2317_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"2317_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55\u201365.","journal-title":"Blood"},{"key":"2317_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1365-2141.2003.04067.x","volume":"120","author":"JJ Lahuerta","year":"2003","unstructured":"Lahuerta JJ, Grande C, Martinez-Lopez J, De La Serna J, Toscano R, Ortiz MC, et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos\/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol. 2003;120:296\u2013303.","journal-title":"Br J Haematol"},{"key":"2317_CR23","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495\u2013502.","journal-title":"N Engl J Med"},{"key":"2317_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/djn439","volume":"101","author":"A Kumar","year":"2009","unstructured":"Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:100\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"2317_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood. 2002;99:731\u20135.","journal-title":"Blood"},{"key":"2317_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/sj.bmt.1702060","volume":"24","author":"R Abraham","year":"1999","unstructured":"Abraham R, Chen C, Tsang R, Simpson D, Murray C, Davidson M, et al. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant. 1999;24:1291\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2317_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood.V93.2.737","volume":"93","author":"DC Matthews","year":"1999","unstructured":"Matthews DC, Martin PJ, Nourigat C, Appelbaum FR, Fisher DR, Bernstein ID. Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. Blood. 1999;93:737\u201345.","journal-title":"Blood"},{"key":"2317_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1182\/blood.V85.4.1122.bloodjournal8541122","volume":"85","author":"DC Matthews","year":"1995","unstructured":"Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85:1122\u201331.","journal-title":"Blood"},{"key":"2317_CR29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","volume":"94","author":"DC Matthews","year":"1999","unstructured":"Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237\u201347.","journal-title":"Blood"},{"key":"2317_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040620711422265","volume":"3","author":"JJ Orozco","year":"2012","unstructured":"Orozco JJ, Zeller J, Pagel JM. Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Ther Adv Hematol. 2012;3:5\u201316.","journal-title":"Ther Adv Hematol"},{"key":"2317_CR31","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","volume":"20","author":"R Mawad","year":"2014","unstructured":"Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Shields AT, et al. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014;20:1363\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2317_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/imt.13.11","volume":"5","author":"JG Jurcic","year":"2013","unstructured":"Jurcic JG. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy. 2013;5:383\u201394.","journal-title":"Immunotherapy"},{"key":"2317_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bmt.1704201","volume":"32","author":"JM Burke","year":"2003","unstructured":"Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32:549\u201356.","journal-title":"Bone Marrow Transplant"},{"key":"2317_CR34","first-page":"151","volume":"17","author":"I Buchmann","year":"2002","unstructured":"Buchmann I, Bunjes D, Kotzerke J, Martin H, Glatting G, Seitz U, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm. 2002;17:151\u201363.","journal-title":"Cancer Biother Radiopharm"},{"key":"2317_CR35","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1182\/blood-2010-06-284349","volume":"117","author":"AS Schulz","year":"2011","unstructured":"Schulz AS, Glatting G, Hoenig M, Schuetz C, Gatz SA, Grewendorf S, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood. 2011;117:4642\u201350.","journal-title":"Blood"},{"key":"2317_CR36","first-page":"285","volume":"91","author":"T Zenz","year":"2006","unstructured":"Zenz T, Glatting G, Schlenk RF, Buchmann I, Dohner H, Reske SN, et al. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. Haematologica. 2006;91:285\u20136.","journal-title":"Haematologica"},{"key":"2317_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.blre.2016.04.007","volume":"30","author":"AM Ali","year":"2016","unstructured":"Ali AM, Dehdashti F, DiPersio JF, Cashen AF. Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: another step forward. Blood Rev. 2016;30:389\u201399.","journal-title":"Blood Rev"},{"key":"2317_CR38","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/blood-2011-09-380436","volume":"119","author":"Y Chen","year":"2012","unstructured":"Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, et al. Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood. 2012;119:1130\u20138.","journal-title":"Blood"},{"key":"2317_CR39","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/eji.1830261218","volume":"26","author":"SC Stocks","year":"1996","unstructured":"Stocks SC, Ruchaud-Sparagano MH, Kerr MA, Grunert F, Haslett C, Dransfield I. CD66: role in the regulation of neutrophil effector function. Eur J Immunol. 1996;26:2924\u201332.","journal-title":"Eur J Immunol"},{"key":"2317_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12185-008-0044-0","volume":"87","author":"R Ratei","year":"2008","unstructured":"Ratei R, Karawajew L, Schabath R, Ehrfeldt A, Grunert F, Ludwig WD. Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemias. Int J Hematol. 2008;87:137\u201343.","journal-title":"Int J Hematol"},{"key":"2317_CR41","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2141.2010.08100.x","volume":"149","author":"C Lee","year":"2010","unstructured":"Lee C, Guinn BA, Brooks SE, Richardson D, Orchard K. CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials? Br J Haematol. 2010;149:795\u20136.","journal-title":"Br J Haematol"},{"key":"2317_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.2910360113","volume":"36","author":"K Bosslet","year":"1985","unstructured":"Bosslet K, Luben G, Schwarz A, Hundt E, Harthus HP, Seiler FR, et al. Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA). Int J Cancer. 1985;36:75\u201384.","journal-title":"Int J Cancer"},{"key":"2317_CR43","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S0960-894X(00)80451-5","volume":"2","author":"SMMH Quadri","year":"1992","unstructured":"Quadri SMMH. A convenient synthesis of 2-p-aminobenzyl-3-methyl and 2-p-aminobenzyl-3-benzyl derivatives of diethylenetriaminepentaacetic acid (DTPA): carbon backbone modified chelating agents. Bio Med Chem Lett. 1992;2:1661\u20134.","journal-title":"Bio Med Chem Lett."},{"key":"2317_CR44","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Linden O, Flux G, Committee ED. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2317_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1088\/0031-9155\/13\/2\/306","volume":"13","author":"R Loevinger","year":"1968","unstructured":"Loevinger R, Berman M. A formalism for calculation of absorbed dose from radionuclides. Phys Med Biol. 1968;13:205\u201317.","journal-title":"Phys Med Biol"},{"key":"2317_CR46","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114\u201325.","journal-title":"Bone Marrow Transplant."},{"key":"2317_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"2317_CR48","first-page":"37","volume":"20","author":"WHO.","year":"1980","unstructured":"WHO. WHO handbook for reporting results of cancer treatment. Neoplasma. 1980;20:37\u201346.","journal-title":"Neoplasma"},{"key":"2317_CR49","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.3390\/cancers15143660","volume":"15","author":"G Winter","year":"2023","unstructured":"Winter G, Hamp-Goldstein C, Fischer G, Kletting P, Glatting G, Solbach C, et al. Optimization of radiolabeling of a [(90)Y]Y-anti-CD66-antibody for radioimmunotherapy before allogeneic hematopoietic cell transplantation. Cancers. 2023;15:3660.","journal-title":"Cancers"},{"key":"2317_CR50","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.V80.6.1608.1608","volume":"80","author":"FR Appelbaum","year":"1992","unstructured":"Appelbaum FR, Brown PA, Sandmaier BM, Storb R, Fisher DR, Shulman HM, et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. Blood. 1992;80:1608\u201313.","journal-title":"Blood"},{"key":"2317_CR51","first-page":"398","volume":"28","author":"WH Knospe","year":"1966","unstructured":"Knospe WH, Blom J, Crosby WH. Regeneration of locally irradiated bone marrow: I. Dose dependent, long-term changes in the rat, with particular emphasis upon vascular and stromal reaction. Blood. 1966;28:398\u2013415.","journal-title":"Blood"},{"key":"2317_CR52","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1182\/blood.V31.3.400.400","volume":"31","author":"WH Knospe","year":"1968","unstructured":"Knospe WH, Blom J, Crosby WH. Regeneration of locally irradiated bone marrow. II. Induction of regeneration in permanently aplastic medullary cavities. Blood. 1968;31:400\u20135.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1038\/s41409-026-02810-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02317-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02317-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02317-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:02:02Z","timestamp":1772697722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02317-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02317-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: During the production process tab. 2 has been typeset wrongly.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-026-02810-7","URL":"https:\/\/doi.org\/10.1038\/s41409-026-02810-7","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KO has contributed to advisory boards for Gilead, Janssen, Takeda and on consultancy basis for Telix Pharmaceuticals. KO has IP in the targeted radiotherapy technology. JL has been employed on a consultancy basis by Telix Pharmaceuticals. VL has contributed to advisory boards for Immedica Pharma AG. The other authors have declared no conflicts of interest. The radiolabelled anti-CD66 technology was acquired by Telix Pharmaceuticals in 2020. All the work described in this report was completed before acquisition by Telix.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}